US drug company Charles River Laboratories International announced on Friday that it was aborting a $1.6 billion takeover of Chinese drug research and development outsourcing company Wuxi PharmaTech.
Charles River is a provider of research models and associated services of preclinical drug development. WuXi is a pharmaceutical, biotechnology and medical device research and development outsourcing company, with operations in China and the United States. Charles River and WuXi announced the takeover in April. The deal has been withdrawn only days ahead of a meeting at which Charles River shareholders were to vote on the acquisition.
Charles River chief executive James Foster said in a statement that he continues...
¬ Haymarket Media Limited. All rights reserved.
